0001193125-22-169395.txt : 20220607 0001193125-22-169395.hdr.sgml : 20220607 20220607173036 ACCESSION NUMBER: 0001193125-22-169395 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20220607 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220607 DATE AS OF CHANGE: 20220607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DBV Technologies S.A. CENTRAL INDEX KEY: 0001613780 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36697 FILM NUMBER: 221002070 BUSINESS ADDRESS: STREET 1: 177-181 AVENUE PIERRE BROSSOLETTE CITY: MONTROUGE STATE: I0 ZIP: 92120 BUSINESS PHONE: 33(0)155427878 MAIL ADDRESS: STREET 1: 177-181 AVENUE PIERRE BROSSOLETTE CITY: MONTROUGE STATE: I0 ZIP: 92120 8-K 1 d286083d8k.htm 8-K 8-K
NASDAQ NASDAQ FR 00-0000000 false 0001613780 0001613780 2022-06-07 2022-06-07 0001613780 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2022-06-07 2022-06-07 0001613780 dei:AdrMember 2022-06-07 2022-06-07

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

June 7, 2022

Date of Report (Date of earliest event reported)

 

 

DBV Technologies S.A.

(Exact name of registrant as specified in its charter)

 

 

 

France   001-36697   Not applicable

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

177-181 avenue Pierre Brossolette  
92120 Montrouge France   Not Applicable
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: +33 1 55 42 78 78

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Ordinary shares, nominal value €0.10 per share   n/a   The Nasdaq Stock Market LLC *
American Depositary Shares, each representing one- half of one ordinary share, nominal value €0.10 per share   DBVT   The Nasdaq Stock Market LLC

*  Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01

Other Events

On June 7, 2022, DBV Technologies S.A. issued a press release entitled “DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

 

Exhibit No.   

Description

99.1    Press Release, dated June 7, 2022
104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 7, 2022     DBV TECHNOLOGIES S.A.
    By:  

/s/ Sébastien Robitaille

    Name: Sébastien Robitaille
    Title: Chief Financial Officer
 EX-99.1 2 d286083dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

LOGO       LOGO

Montrouge, France, June 7, 2022

DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

 

  •  

67.0% of subjects treated with Viaskin Peanut 250 µg met response criteria at 12 months, compared with 33.5% of subjects in the placebo arm

 

  •  

Pivotal trial met primary endpoint: lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 22.4%, exceeding the pre-specified threshold of 15%

 

  •  

Safety results were generally consistent with safety profile of Viaskin Peanut 250 µg observed in children with peanut allergy ages 4 years and older in prior clinical trials

 

  •  

High treatment compliance rate observed over trial duration, with low rate of discontinuation due to adverse events

 

  •  

DBV will hold a conference call today at 5:00 p.m. ET to discuss the results

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that its pivotal Phase 3 trial EPITOPE (EPIT in TOddlers with PEanut Allergy), assessing the safety and efficacy of Viaskin™ Peanut 250 µg for the treatment of peanut-allergic toddlers ages 1 to 3 years, met its primary endpoint.

Viaskin Peanut demonstrated a statistically significant treatment effect (p<0.001), with 67.0% of subjects in the Viaskin Peanut arm meeting the treatment responder criteria after 12 months, as compared to 33.5% of subjects in the placebo arm (difference in response rates = 33.4%; 95% CI = 22.4% - 44.5%).

DBV intends to further analyze the data from EPITOPE and explore regulatory pathways for Viaskin Peanut in children ages 1 to 3 years, given the high unmet need and absence of approved treatments for this vulnerable population. Separately, DBV continues productive dialogue with the U.S. Food and Drug Administration (FDA) on the protocol design of VITESSE, a pivotal Phase 3 trial of the modified Viaskin Peanut patch in peanut-allergic children ages 4 years and older.

LOGO

 

LOGO

 

“Most peanut-allergic children are diagnosed between 1 to 3 years of age; however, there are currently no FDA-approved therapies for this age group. Furthermore, there is growing evidence on the benefits of treatment from a younger age,” said Dr. Hugh Sampson, Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai, Director Emeritus of the Jaffe Food Allergy Institute and Chairman of the DBV Scientific Advisory Board. “We believe these positive findings support the potential clinical benefit of Viaskin Peanut in this important, and underserved, population.”

These results represent the second and final part of the EPITOPE trial, which enrolled 362 subjects ages 1 to 3 years, of which 244 and 118 were in the active and placebo arms, respectively. Enrollment was balanced for age and baseline disease characteristics between the active and placebo treatment arms. The median subject baseline eliciting dose (ED) was 100 mg in each treatment arm. A double-blind, placebo-controlled food challenge (DBPCFC) was administered at baseline and month 12 to determine a subject’s ED at each timepoint. A treatment responder was defined as either a subject with a baseline ED ≤10 mg who reached an ED ≥300 mg of peanut protein at month 12, or a subject with a baseline ED >10 mg who reached an ED ≥1,000 mg of peanut protein at month 12.

In an additional pre-specified efficacy analysis, treatment response was defined as achieving an ED ≥1,000 mg of peanut protein regardless of baseline ED. Using this response criterion, Viaskin Peanut demonstrated a statistically significant treatment effect (p<0.001), with 64.2% of subjects in the Viaskin Peanut arm meeting this treatment responder criterion after 12 months as compared to 29.6% of subjects in the placebo arm (difference in response rates = 34.7%; 95% CI = 23.6% - 45.7%). The response rate observed in the placebo arm appears consistent with the approximately 22% natural resolution rate in this patient population.1

The EPITOPE safety results were generally consistent with the safety profile of Viaskin Peanut 250 µg observed in children with peanut allergy ages 4 years and older in prior clinical trials. No imbalance in the overall adverse event (AE) rate was observed in the trial between the active and placebo arms.

LOGO

 

LOGO

 

Overall, 21 subjects (8.6%) in the Viaskin Peanut arm and 3 subjects (2.5%) in the placebo arm experienced a serious adverse event (SAE). Only 1 of the SAEs (0.4%), which was mild periorbital edema (swelling around the eye) in the Viaskin Peanut arm, was deemed related to treatment.

The most commonly reported adverse events were skin reactions localized to the administration site, the majority of which were mild to moderate in nature. Fifty-five subjects (22.5%) in the Viaskin Peanut arm experienced an application site reaction that was assessed as severe by an investigator compared with 10 subjects (8.5%) in the placebo arm. Based on investigators’ reported observations from examinations of the skin at each study visit, using the skin grading systems defined in the protocol, the severity of administration site skin reactions following patch application decreased throughout the course of the 12-month treatment period.

Four (1.6%) subjects in the Viaskin Peanut arm experienced an anaphylactic reaction determined to be related to, or possibly related to, treatment. Among these anaphylactic reactions, 3 resolved with a single dose of epinephrine and 1 resolved without epinephrine. All anaphylactic reactions were mild to moderate in severity and were characterized mainly by skin and respiratory symptoms.

Eight subjects (3.3%) in the Viaskin Peanut arm discontinued due to adverse events.

In the 12-month treatment period, the trial completion rate was 84.8% and was balanced between the Viaskin Peanut and placebo arms. Mean subject compliance to daily patch treatment was above 95% in both the active and placebo arms.

“We are thrilled by the topline results of EPITOPE, our second Phase 3 clinical trial to evaluate the safety and efficacy of Viaskin Peanut,” said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies. “We are grateful to the toddlers and their parents, caregivers and allergists who are contributing to a brighter future by having participated in this first-of-its kind trial.”

Following the completion of EPITOPE, all eligible subjects had the option to rollover into EPOPEX, a long-term, open-label extension study of Viaskin Peanut. There are currently 304 subjects (88% of all eligible subjects) enrolled in EPOPEX.

DBV plans to present full EPITOPE trial results at future medical congresses as well as submit them for publication in a peer-reviewed journal.

LOGO

 

LOGO

 

“The EPITOPE data advance our understanding of investigational epicutaneous immunotherapy’s ability to induce an immune response with minimal amounts of allergen,” said Daniel Tassé, Chief Executive Officer of DBV Technologies. “These results further inform EPIT’s potential in other food allergies and immunological conditions, which are areas of research DBV remains highly committed to pursuing.”

DBV will host a conference call and live audio webcast on Tuesday, June 7, 2022, at 5:00 p.m. ET to discuss the results. This call is accessible via the below teleconferencing numbers, followed by the reference ID: 23143278#

 

  •  

United States: 866 374 5140

 

  •  

Canada: 866 455 3403

 

  •  

United Kingdom: 808 238 9813

 

  •  

France: 805 102 712

A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.

About EPITOPE

EPITOPE (NCT03211247) enrolled 413 subjects (51 in Part A and 362 in Part B) in approximately 50 centers across North America (Canada and the United States), Europe and Australia. The EPITOPE trial is a two-part trial: Part A was designed to assess the safety of Viaskin Peanut 100 µg and 250 µg and to determine the highest safe dose, and Part B was designed to assess the efficacy and safety of the selected dose. Based on the results of Part A, the 250 µg dose was selected for Part B. In Part B, subjects were randomized 2:1 to receive Viaskin Peanut 250 µg or placebo.

The primary endpoint was based on a responder analysis after 12 months of treatment with the selected dose of Viaskin Peanut. As a secondary efficacy endpoint, cumulative reactive dose (CRD) was also evaluated in EPITOPE to establish the total quantity of peanut protein that triggers subject reactions at month 12 of active treatment versus placebo. Serological markers were also measured at baseline, 3, 6 and 12 months in order to characterize the immunological changes in subjects.

Following the completion of EPITOPE, all eligible subjects had the option to rollover into EPOPEX, a long-term, open-label extension study of Viaskin Peanut 250 µg. Now that the EPITOPE study results are publicly available, subjects enrolled in the EPOPEX study will be unblinded to their respective treatment group in EPITOPE.

LOGO

 

LOGO

 

About DBV Technologies

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding DBV Technologies’ Viaskin Peanut, such as the regulatory pathway for approval by the FDA in children ages 1 to 3 years and the planned VITESSE Phase 3 clinical trial in older children discussed in this press release. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. These forward-looking statements may be impacted by market conditions as well as other risks and uncertainties set forth in DBV Technologies’ regulatory filings with the AMF, DBV Technologies’ filings and reports with the SEC, including in DBV Technologies’ Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 9, 2022, and future filings and reports made with the AMF and SEC by DBV Technologies. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Investor Contact

Anne Pollak

DBV Technologies

+1 857-529-2363

anne.pollak@dbv-technologies.com

Media Contacts

Angela Marcucci

DBV Technologies

+1 646-842-2393

angela.marcucci@dbv-technologies.com

Katie Hatcher

+1 312-397-6621

khatcher@webershandwick.com

 

 

1. 

Peters RL, Allen KJ, Dharmage SC, et al. Natural history of peanut allergy and predictors of resolution in the first 4 years of life: A population-based assessment. J Allergy Clin Immunol. 2015;135(5):1257-66.e662. doi:10.1016/j.jaci.2015.01.002

EX-101.SCH 3 dbvt-20220607.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 dbvt-20220607_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 dbvt-20220607_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Entity Address, Country Entity Address, Country Entity Tax Identification Number Entity Tax Identification Number Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, City or Town Entity Address, City or Town City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Fair Value Measured at Net Asset Value Per Share [Member] Fair Value Measured at Net Asset Value Per Share [Member] Adr [Member] Adr [Member] EX-101.PRE 6 dbvt-20220607_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g286083adsp001.jpg GRAPHIC begin 644 g286083adsp001.jpg M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$ (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @," M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# __$ :( $% 0$! 0$! ! @,$!08'" D*"P$ P$! M 0$! 0$! 0 $" P0%!@<("0H+$ " 0,# @0#!04$! 7T! @, M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( '0 90,!$0 "$0$#$0'_V@ , M P$ A$#$0 _ /W\H * #I[8_#%&WD&WE83('<#].E&WD"\MCB/%WCK1_"<2 MQ3.U]K%V?)TS0K',VIW]PX^2..&))&C!SD,R8/8,>*VP^#JU).I*\:-_B:]U M)>K2_*QC*O&-XQLW'HG^B.&@U;XQ^)/FL])T;P98D[H9=4,E[J,L385=\&&$ M<@!W$&*,@@#CH>M0P%%OFDZSCT@T[-?X4U;IJ_F9:+_]/TJ4UT>P]O(* "@ H * "@!K':I( M!./X1C)QV&2*/T_0:739'"^/?%B^%-&,]M&MSK=\Z66@::Q^:_U*62.-$50< MLL7F"1NV!COQT86BZU1Q7)'=['GMK86/@'3?^$U\8>9K M?CS5U406\I$EP=0G^:#1M'@02K;B/S!%)-&A("$C. &[*M6=>HL+AGR4$U'3 M1-+KZ>6O0Y81CAOWM7WG+6V]NG6Q>L=+^)OC-/[1U/7&\!6$^)+;2='M89-5 M,1RH^W75P"48QX(P<@G[J8Q42>%PGNQIQK5%\3W5^N_5/3;0V2JUK2C4=*E] MFVC[+;Y]31;X:^(85!L?B?XQAF7D&]EM]1@8KRH>WF15";NH!Z5'URG_ - L M/N7Y_P###]A57_,3/3S,1O$VM^&KQ?#GQ1M+#4- U'_1+/Q9!:DV,TT@,2VN MIVVTK;.RD@OB/:6(7W1^9"T-U\*-:;X;:[=)!<6LDAEB\/ZA?,HANH)9&9A8MM+$ MEN=[ [V*55_K-.2GKB:=VY?W5I9_-]M.Y;7U>K>G[N'E&RBME*^_W)]3WU&# M#(X'\ORX_*O,E)+_VW_,K^'(I/&OQ#U[Q!??O M]&\'WCZ1X;MV^:"/4D*)?:A& H#2YB<[BQ*^;&1C&"56L+A*5*"M.K&\V_BW MU2:LNRV>E_4JC%8B=2B6BT6FC1[BH ]MHQ^OK7D[2WWN_3;_/\ ZXZ M1Y;64=OQ'8I_,=EV,37]#T[Q#I5YI.J6T=S:7,,J%)5#>4YC98YXB03'-&6W M*PY4C(J\-4GAZRE!VU3:[ZIV?DR)TXU:;C)6M>UO1KS/&?"MG<:[X,\7_#GQ M%*UWJWAZ2[TV*:_3%,=NG;H-?[I_ <>F1D?E0FEU4?73R7 MXC6C]#R/P8/^*S^*VP S_P!J:0%W<\?V8Y@4C\1QZ$>U=M9N-#!K:+^[5O\ MR.&A_O6)OI;;_P EL'P5"GP5&[X:ZDUC6)+YCS(;LWI$C2D_-YFU8AEN<*O8 M"C,VXXA*.L8V2:VM=[/L3E[_ 'OM2;LFU]GMY?Y#VMT1XGHY9?C;XL$7^J/A33&NPO(%P?[+$);'1O M*W=<' ;MFO6J17]F4):*2KM6>]E&I^'1>9Y^V)JI?"J7R^*!/\%_+&@>(O+. M;?\ X3/6A"N<@1*EF@4?[ VD #C QT%88_2I'I:*^XZ,)I3?D>S9 [@8]\8Q M7"M=M?0VNEUL ([$?@1VI72=KI/M_P =K>09 [@8]P,8HNEU2L*Z75*QY=X MJT+XIWFI^?X-\9^'= TP6L*?8-2\,?VM.]VC2&65KQ;J(B)D:,!-I*^63D[^ M/6P=7)Z=+EQ>$K5*B?Q4ZB2MTT;6QX.983B&OBX5,MSBAA,-C6P:KSYN9 MM6:JTO=4;+XE=WV/.-8\6_'+X+T6R:\LYU57-O>1V-W<)!/R?D+Y^4\5Y>99?6P M%;ZM55[IN,XJ7(U%[WE%:72U5T?39#G6#SS"1Q>$E&+CR*I14HSJT93A&7+5 MC&I+VGQ-V2^% M]R#PS/)X(^(&L>%[M6_LKQ==3Z]X?F4%([>\X!N< M8Z?D<'M7F+?9QY=-=/N^[\CT5HEJK/:P[/M_G\J=@^9BZ[K5EX?TO4-5OF"6 M]A:R7#AI(HO,VJ=D,;3.B^;(X"*">2<#GBJI4)UIPI4K:R7->]DKV;T3LM?D M34J1I0YI;+9*U]%?2[1XQX7U";2_"OBWXI:U"T>I>(4N+JVM,&+[/96T8M]* MLU^T!,[I1N+C=N4@J"1@^K72E6I8.D]**4G?R3>ZN]G;9:GGJ7+"IB>5\DER M*-O>O==-K:=SM/A7HD_A_P %:=!>DM=WTESK%TVQXP)-1D,JQ[955E983$"" M.H."1@G@QU>,\2Z:C*ZBH;=5HWH]-?P^X[,,E"@IN48QDKZNW+I?WK[6Z]M3 MSOQ7\=Q:^+C\/? WA:[\8^)H&S?S1W6-$TQ A9S=3Z1;ZE=>;$^P212V< 3= M]_.,^SA\BC/"K'8^M'#T(M+V;;A6EJDI1C-*/*[W3N[I7MT/AL;QI4AF+R?( M,!/&XA7;K_\ ,-'E3E.//26*DY*W*URQLVD[==*#1/VC+YI);OQE\.- 0LK0 M6VD^']5U@+'DMLFGU1K9RVT[>$ &,]\#-5.'*?+;!XNO:^LJL(LFZN>Y=A=N6%+ 3JZ:W4JE2M3VT2:I*^K=KJ*]D\/6NN66CV- MMXBU"TU?68HV6^U&SM#IUM*S#R>2!$8U(WGE2>]>1B'AYU92P].5* MD[KM://*VENNZ9N5B=9 M7907.2.< @]\ 8'3../446M:5VN756_K44W32BI17,](W5[K71IZ?@SY9\>? M#+7O 6OR_%CX/0E+V#_2O%/@.U$D6G>++<&19F@M8F$:7OE7$TW",WF01-$ MP9)?J\'F=''86669FE*=11C1Q#2O2Y5>SDK.\G&,5*TF^9\SU;?YMG/#F*X? MQG^L/#<_J]/#\]?'8-2E*.)3D^?EC-5%%QIU*K2C*DDU&UK)QZJUUO0_CKX% MCU/093I_B?1I$N5LVD*:EX:\26Y+/IM\=D;HC/&R*^$60!7&#&57RZN$JY5B MN23OAJGPOI..CNK]K^\KZ>EF?59%G>&SW+H8N,7&M33C5H.RE"K"3A+9O=Q; M5I;-72>BGL[W3OB;H[^$O$['P_X\T21976,B#4++4+=BBZKI,BE6FB=5)80O MC:R@-C##.M%X2LJV'][#2=TNG+>UGOIV_J_H4G&O"5&K[M2.D7Z:I_>3P>(O MB3X*(TS6/"USXPTVT3R;77M&9C>W%O$1M>\M%65_.$7&2JY*L2V2,CI8;%M2 MIU8T)RU:D[*^SLM=6^B^1:G4PT?92BYQC\+797].C+K_ !6*'Q8JG%+O=?FO\P6+_Z=2T]/\S+3 MPQXB\;W4'B#XD;-"T71W^UV?A2VG#6C>3^^:[UFX9RCJN/FRBG:K#"T*I#"1 M=/#-5*LM'+=:;6[W>UNVI-.$L34R^?EY+N03W[?%/7K32],C ^'GA MZZAO+[5((2MMK6H6.'ATZ $J'LD:0*<*P(5F.TH%.4)/#0=5IRQ-2\(K=K5/ MFU?:+[[A6E&56-.+4<+2]^4NFBDOS:.1\=?$C7OB!KLOPK^#T\>_8J^*_']I M*\FF^&+=2M*[E* MB(-HQG/3]/Z>P%>99)MKW4[:>E_\_P/;BI)>\[OO_20 M^F,* $P!V]_R&!^E"5K]+@ERWMI?-0A 7'(.!D8Y'/?!]ZA1Y(\M.*5FF METNK6W]".503LK=UY=5\U='S=X^^%VO:%K-W\3?A'<-8>*?ENM<\*[6&B^-% MC=FGBNH?M<,<%^Z23.)0I+28*-!([R2?2X'.*5?#1RO-HJ5-*U.K)RYZ=M%9 MI232OIO;1.ZV_/\ .>&\5@\PJ<1\.5*E#&3=Z^'IQA[.OI'FYN9QEK*$6[/5 M[:VOC:)XP\"_%>X@T[6))?AW\6=+8P2V+Q>7/6+5FN3JVHRDXKK=I+R[]&4<4X+,I4Z&/=/*,V MC[M7#U7.BX5%KRTIUXPC+I;E=371-O1=\S?&+PU^XMDT;QY8#'D7-QC3M3CC M )7SBMQ&DCL,C<%;D#GGGSHPRJHFZM6>$K)ZP:;AIOROV>MM+>]?5Z=OK'+' M4TI8>,<33EMS3A>V_,JBE&+6EK*.MXV?NN\7_"7_ !=G/EP_#6S@;/$MYK$1 MB0DX!V^8A8#KQ(/ZTU0RE;X]>7NM?H_R%'$XZ3Y?JWL7_P!?8)?C;\REJFB: MO>V;:O\ %GQG;:!H<+&670M.N8=*TWRTR[PWE_)*SWF^%6C,*-*[ _(P8UK3 MBY5%1RK!SQ=72TH1F]+I1;T=KR:W<5V\N?&8S#8"DL1G&8T,OPZ3]VM4IKGM M%RDHOG3;Y4W91D[/2[W\V?Q7K_Q3N!X ^"^GR>&?AM!,UKK?Q'M[2>W4Q*C- MJ.G:#%.(2;V7S(XQ,VZ7>Q=BBJV_UUA2]O[O;B2\O;B3+S3L= MW?:H.$"K@#YW&8VKC:KE5ES+5*-](I]%_F?!X=P2P6 348J/MJK24ZT MHIWE.RM=OF=HJUY.VYW@ Z >V,>U<5K/M8]I/Y"]/P_I1:W]=@"@ H * M$/2C\+?H"T]$,VD>G'3DC\,8HM&Z;6L=A.]N6*48_P!=+?J>6^.OA%X&\? S M:SI2VVLPC%EXDTAFT[7K"1.89+>_A'[QHFPRQW"S1Y&=E>I@LWS#!VC3JNI1 MB[>RJM.GR]4HM25M7K9:O5'@YIPOD^:QE*K@J5'&27N8FCSX>M3FOAGSX>5* MM+-\EQ-GC(I2J\E-?#'GK2Q,G:]KO6W7H2-\/OVG[P>7-\9O#=I&3AI+/0+ZT_P_:,"I)33[>Z)F)(;( M+QH0<-&0:BIQ!&C3]GE.#AEC5U[2*A*HXI6CJX)Q:=G?FD[I:Z7>V#X%JUY. M?%&(U?FC1JJM3HTY-WERQCB7#E7!&H523R6QD]SS7SDIUJM25?%8BIB<1)*+J3E*_* MK65G)K2VCW/NL)@\+E]&.%P%"G@L+!MJC2A%1YFVY2NDGJW=K;[D:@4KGH>O M7C'IV-0UMR^ZT=3M9I12\NC]=/T8\<>V/TQ3V^0EIY6Z!0 4 % !0 AX'3.. MW3I0 BMG/&-OU'\U'Z4 ?GQ\+O'/C/4O^"@O[1W@74/%7B"\\%^'_AWX4U#1 M/"MSJMY/X?TF^N=+^'LMS>:?I4DIM[2YF>_O"\D<:LWVF3)^:O5Q5*G3RW"U M(12G*.K_ / OU."$YRQ5*JZL$W;6S5>^O M_;D?N78N,Y?7I4WI&-.32]'2_P V??F1&.,#)/MDYQT ] *\P[!XZ#MQT]/S M _D* %H * "@ H * "@!N<$\XQ^&*EW;Y4K)=?Z_S%:UWT70_+C4OC/\?OVM M/B3XW^&W[-7B6T^%'PM^'5[<>&O&_P 6M0L8M5UO6]86^O+9H_!L:1GR8S#9 M2/"89K:?RMEW)>PK<6L-Q[L<)0P-&-;$6JU'9PIR7=)6:EVW;:LFN^_E/$3Q M=7V%*4J*U3E%VM:[6L6K7M;?J;H_9;_:O^&%K/XG^%?[6_BOQQXGMX)+N[\' M_%+2WU3PMXINHXY)A81R7VNWKZ +AE$"RQ*)%+KFZ@0-*D_7L)7_ '4\#2H1 M5O?A""EZW45ZO7IUV=/"8G#^_'$U*MOLN4W^;9X[^Q9X]U_XF_MM?'KQGXK\ M,W'@WQ5>_"[1M)\4^&+AMSZ1XG\+W'@3PQK\$8,KE+1K_299H%#G*6)^">G^!O!>@1R>7;S>*?%&J:C;:/]E]B5=6^YO_(=:52.82]G=ODD MNNW[KMVT/H*3]DC]HKQPDNO_ !+_ &Q_B/IWBZS5YL,RP>&DJ2R^E52V%/@9^TWXFA^(?A+XC+:67PN^,]EHZ:&6 MUY[MK!O#WBQ(V\LSFXN=.C=@99H&U"PEDN+B"\?[!IB:%#'T:F+P<8T)4OCI M122T@W=1AHE[MEHDW?[5QPJRH5(TIR[W.__:U\>_$CX&^* MOA%\;-$\7:DWPJM_%NE^!?BQX D%H=*FT?Q UZEEXOM[B2W\RUNK(2W*MLG0 MS3KI4?S;61N3*Y0Q%.MA*E&*J*$IQJ2BN:ZE3LDVN;:^FUKZ6N/%\]"I3KJ< MO9W47!-I?#+I>W1'W1!,DL4 MKVOI;Y?/;H=J:JQ4X^ZK7T_X!\%?!SXF_$KXV_M9?%K4M#\3ZE:?L^_!U)?A M]!HBPVL>G>*?B%;K):ZC>K2GY M6L=_Z"TP"@#G?%+:DGASQ"VC@_VK'HFJ-IH4 L;]=/N39! >"WVL1<&KHN4: M]/;DNM.NZ$FDJB=]%I^!\!?\$NX]#B_9DMVTUD.M3>._&$GC!6<&X374N;:* M)94X9/\ B2+H[@%N2Q%'EB^14]=OYI6W?H>=EJH^SK/::GI] MW;[S]%Y #U!Q]<=B#T_V2W<<@=Z\9IRC9+Y:7/1C-J5OA2V=F?F9\%XM+B_X M*4?M2#267RV^&GAB6_6-@R#6);?X>'41D' ?S5&]>H?S 0.,^U7?L\FP-.47 M%QG*6MOA:M'9[VCKT_3S:3C_ &A5L]I?HB75QX=7_@J%H+Z[)"EXO[/[CPQY MTJQYUYKS4(V2W5O]==MH3ZX$0A9O30 M_,'_ (*B?94^&GP?E@++XJ@^-WAYO#/DEFG+'1]<%V(XE'S#S4TU21DJ[PC@ MLN?>X=5L5BKIRHJC[RC_ #\RYM[?WK:GFYE%7PRIR2G%J]_EY=_ZV/N3XX_# M33OC!\)?'OPWU6"*:/Q5X>O;*R:1]JVNMP#[7X?OPX4^6]IKEMI]QG!&8B&W M*3GR\-5E0K0J?#&-17_PN"3Z^MM>QVUZ3J82=.37,MNBO?3IV/SF^%7[7&J? M#3]AWQ9=>+)"GQ@^!]]>_!Q-!U./;J4>M1,UCX'DU.U\P/-:VVC(?.NUW^:O MAJ_D03,G[WUZV"]MCZ%6,;8>LU)RV6KCS7LG;=-Z:W=KZV\REBUAL'*A.[K1 M3BK)=FENU^1]G_L;?">^^#OP#\%>'M8\P^*=?BNO''C%YWW3_P#"2>*3!J-S M!,!$N)+2S>QL&SR#IH^\69CY^98A8C&SG3NJ,8Q@DTN:\$HMZ-Z-IVUO:UTM MCNP%*5"@E4LY2;E[M[6DTUNEK;?\SZI Q^']*XMOD=,4U>XM(H* &E1[CG\L M# _E4N2A9[)"MNMKGY%W&B_%?]@;XJ>./&GA3P=J/Q-_9A^(^MCQ5XOM]!MQ M>^+?A[>RM>+(8+6*6&-;>WFU&V6.XD5[>>R@C@FDMYH%GC^BC*AFE&G3J5%2 MK05HR;6NB;T;5T^6]D[K36SU\B-"M@JKG"+G!MMQ5_->>U^W_ ]$N/\ @HKH M/Q&MI/"7[.7PR^(WC_XK:Q$UIX>T_5]!L-+\+Z/?R*PBU'Q9J\>OR)8:9:'] MY(2Z0S>4T8N8=VY>:.51H/FK8B$8?W97^6O+TOKNMK/=;RQM6:Y*>&ESKR?_ M ,B>5_L5> ?BCX*_;%^.C_%>*:[\6ZM\/K37_$VNV.GW2>&;CQ'XKU+P=XDU M#3=&U&5/)N(;&2^DLU6.20*FG%5>0)YCZYA7I5L%2I4;.%/W4]M$I=/R1SX2 MA4^M.51.,KW:[?/3\C'_ &IOA'\2?B1^W)I.H?#9[K1O%/@_X1Z1XU\&Z]>6 M=TOAZ\\5>$]9O[JS\/7VJ>0L%E'?Q7,MO)(TLF%8AU2)Y9K?IR_&8:AEOL,0 M^6.D;W5[MU5LVKV4F[*[:6B;LBZE"?U^33:]R7_N+_(]B@_X*6>"?!-N/#/Q MO^&GQ.\"?%/1U^R>)?#EGX>TRYT:758U 9_#M]>^)8)+G3;K,"/"OQ*_;8^-7@KX MX?$SP=K/PV^!'PMNQJ_PL\(:M(D'B#Q5X@MK[3KQ-8U>WEBS_9LEW86\TLJ1 M1P216MM:VDUQNFN3K6K4^NKWP]C4Q%> MG5;:IRM)>C::_ _5F0*J@YQCOUZ@KR .A.,UX+YI+D^&4MOEK^2/7:-?V]O!WB>ZTN=_A+XRTVU^(OBZ6U?;9W'B;X;6EO8+ MI.IP &(?:[ZY\+.KLA>2+5=7,;9BDQ]'1S2%+)JF%:4L337+%W2=K-)[-KE6 MN^MM]3R:N E4S",EI3O=JVFZ/UP5%4+@8V@!>V .W'UKYVYZZ7*DOY=/N'T M% 'GGC#XE>$O!.L^#M$\0:QIFFW7C#5[G2;$7VK:;IGV?R-#UK61>3QWUY"[ MVLDFB_8$:-'!N=0MH^#( UQI2G!S2LHK3?\ 3MN_^')'O"VG2/Y4=[XCU?3]#LY) M#M_=I<:I<01N_P RY4,3\PJHTZE[1CMTCT^[;83G&*NW9+_ACSSQ+\7/!WA' MQ3\.M"+8+_2K;P]I.F^"]%MM58I+.Y@NHXUN% MD\M<;F?!&=8TJTHSNV^1K1M]79:>7X$JM1CY>B/1].\4>%]5TJRUS2_$&A:G MHFHR>5I^L:?JMA>Z5?RB9K8)9ZA;3O!A2G#XHZ>8S0O%OA/Q1%58 M+CS P$4A5L]!FATZBLG&UM4GY=5Z=7T'S1WZKJ9VF>+O 7BK4;_3-"\2>$_$ MNK: R_VGI^DZOI&M:CH*M*O!:7BO5KR^ M?]=B7[-[Q3MY+]3B_ GQL\&^+?AMH_Q0U>^T[P-H.JW^NZ=&_BG6=)T^WM[C M0M?U?P_-&=2GN([5VGET>>=$$A;RRPZQMB73JIVY=8]-_P"MAJ45:VEM%H>H MVNOZ%>Z4NN66L:7=Z*UHU^NKV]]:S:8;%%D=[S[='(8/LJK#,6EW[%\E\D;& MQ+A46G+9K;Y?U]S[,:E%==CGX?'OA;6-#O-;\)Z]X<\70PQZC'9G0_$6C7-I M>ZCIM@;^73AJD5V]K;2K!);R2/)(!#%.L\F(OF+I4JO,TUV_';2VM]DM==-] M YXIZ$4_Q!\+Z#H>@:UXUU[PWX(&MV=I-'%K_B?1+>U6\N;..YEL+/5I;Q+7 M56B!?$MI(\WEOITMV_P F'/$V]8\6^%O#MM87NO\ MB30M"L]4NH+'3+O5]6L-,MM0O;I&DM;2QGO;B-+NYFC5FCCB9V<#*@U*I2]Z MR>F_E_E_P/(3J1C97]#H%((!'3MVJ(KENNQ2::TTL>2_$+PO'K7BKX17;:+' MJD.E>.-6N-3N9+!+I-.TV3X9?$&QBFN9&1C#;-K-YI4:#(7SY82,/AAO2J.G M&45IM;7MY;?@9U*7/;EER6[+_)H^([7X;^+=&\._%S0O%UG\1-0\1ZQXQ^(N MHII&E?"7PKXZM/BA8:[KVJ:KX0N+3XB7WA"]@TF%]+OK#3(X?$6K6']B'3S; MKBPM;::7K52/[MQY8I=.9^[:]]$U?O;EZV;TN<_+.G>&L^7KWOKYVM>V_0]_ MTO1D\'>.8KWXB>$O$WBNSF^%WP]T+PYXK_X1.]^(E]H-]X>MM=M?%NA:G_PC M6DWUWI>J:A>75EJ,NIVEC#::DS"-I0=.BB,N7N/DFHN,I:)VO>2::L[.RTL[ M66G9CC=M*4'R_P"2].YSWB'P/8^,OBU^S9JVD_"?4M"\"^%O$GQPU+4;;4?" MEIH^F07EYX?M[?0_$^IZ)&-VFIJ^HK/-9QZO:VE\TPWRVL$B*S1"'VOM(MH MM&M]0URWUC0F\/Z1=:A:+$EO>2V-YK4%K,Y8VL5S,\92-7%$*JM#FE\,KV>M MM&EUZ/7O=7UEN7FOL/1=SE_$^AVOC34_@7;?"WX;:_X!U;PK\0_#7B;7=5U' MP3J_P[MO!O@72K:5O$_A62YETZSL_$1U>U:/1%T;2[J_M))9?M\C/%8Q2W%* M7+[2]1235DN[N^VSOUV2:M9*R5YZ>XU8\^^!W@O7/ ^E_#'4_B9X"\2ZGHUK MX8^)VAV^DS>#-8\4W?@/Q-=_&'Q+X@BUJY\,:7IE[J%L/$OAJZTV.#4K>P8Q M1Z%!%(\4>H%E( M8_ ][:_#G5_CMX"U.R^%FJ6-MX3OO%EC9>&$T/7-9L?"&I2VD-Q>W?BAK77X MO#DMI'<:JW@QI6MGGU0)24DK+GBY*,DY*[MK=>\_>M%:>5^H?VX:7ZJ2>KO;Y+LMG<7.UM&UE^AAZ M/X \3Z1XD-[XGC\<^'$U3X8?#"QT37M*^$>E?%**P@TGP3I&BZ[X,FMV\(Z_ MJOA?4K+Q';ZGJC6TMK'87AU;>YDFMG0S[6&NBEK)OWFMWH]&NBMO==-!IS7V M&MOZV*,'PZU7P=X%\,Z\=!^)6J>.=%B^+UWX-\'^*_A];_$?PS?Z#XPU?3;V M+X:6C7>G)H\9NK:XFEB@DL6J,X^_%./+)*[NTUO MJGUM>S[W2T3;2]G*I9ZT^796O>_S6UC]%-'>X?2M->[LTTZZ>QM7N=/B=)([ M"X:!&FLXY(P%>.&0M&K $(.*\^>DGY'5!.$4M[&D0#C(^[T[8_SQ^(!Z@5G M>WD:_H-V+D< 8].!^('!_&ES-=;6"R[">6O'!&W'0L.BE0#@\C!Z'(S@]0*$ MWW"R72UAQ5?3'T)7]01Z?S]:=W]P6MY"%%../NDD8)&,Y!Z'IST/'3T&"["R M[">6@_A[YY).",\@$\'G''8 = %=KJ%EV$\J/CY1\HVCKG (."T'Q-ILVC^(M&T MS7-)N#&9]-U:QMK^RE:&1)H'>VN8WC,D4T<4D;[=R/$CH0R*1<)RB]':PFE: MUC"\-_#GP+X0N)[WPWX6T?2=0NH?LUSJEO:JVK7%JKJZ6<^K3%[R:R1U!2W: M GRAPHIC 8 g286083dsp001.jpg GRAPHIC begin 644 g286083dsp001.jpg M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$ (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @," M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# __$ :( $% 0$! 0$! ! @,$!08'" D*"P$ P$! M 0$! 0$! 0 $" P0%!@<("0H+$ " 0,# @0#!04$! 7T! @, M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( '0 90,!$0 "$0$#$0'_V@ , M P$ A$#$0 _ /W\H * #I[8_#%&WD&WE83('<#].E&WD"\MCB/%WCK1_"<2 MQ3.U]K%V?)TS0K',VIW]PX^2..&))&C!SD,R8/8,>*VP^#JU).I*\:-_B:]U M)>K2_*QC*O&-XQLW'HG^B.&@U;XQ^)/FL])T;P98D[H9=4,E[J,L385=\&&$ M<@!W$&*,@@#CH>M0P%%OFDZSCT@T[-?X4U;IJ_F9:+_]/TJ4UT>P]O(* "@ H * "@!K':I( M!./X1C)QV&2*/T_0:739'"^/?%B^%-&,]M&MSK=\Z66@::Q^:_U*62.-$50< MLL7F"1NV!COQT86BZU1Q7)'=['GMK86/@'3?^$U\8>9K M?CS5U406\I$EP=0G^:#1M'@02K;B/S!%)-&A("$C. &[*M6=>HL+AGR4$U'3 M1-+KZ>6O0Y81CAOWM7WG+6V]NG6Q>L=+^)OC-/[1U/7&\!6$^)+;2='M89-5 M,1RH^W75P"48QX(P<@G[J8Q42>%PGNQIQK5%\3W5^N_5/3;0V2JUK2C4=*E] MFVC[+;Y]31;X:^(85!L?B?XQAF7D&]EM]1@8KRH>WF15";NH!Z5'URG_ - L M/N7Y_P###]A57_,3/3S,1O$VM^&KQ?#GQ1M+#4- U'_1+/Q9!:DV,TT@,2VN MIVVTK;.RD@OB/:6(7W1^9"T-U\*-:;X;:[=)!<6LDAEB\/ZA?,HANH)9&9A8MM+$ MEN=[ [V*55_K-.2GKB:=VY?W5I9_-]M.Y;7U>K>G[N'E&RBME*^_W)]3WU&# M#(X'\ORX_*O,E)+_VW_,K^'(I/&OQ#U[Q!??O M]&\'WCZ1X;MV^:"/4D*)?:A& H#2YB<[BQ*^;&1C&"56L+A*5*"M.K&\V_BW MU2:LNRV>E_4JC%8B=2B6BT6FC1[BH ]MHQ^OK7D[2WWN_3;_/\ ZXZ M1Y;64=OQ'8I_,=EV,37]#T[Q#I5YI.J6T=S:7,,J%)5#>4YC98YXB03'-&6W M*PY4C(J\-4GAZRE!VU3:[ZIV?DR)TXU:;C)6M>UO1KS/&?"MG<:[X,\7_#GQ M%*UWJWAZ2[TV*:_3%,=NG;H-?[I_ <>F1D?E0FEU4?73R7 MXC6C]#R/P8/^*S^*VP S_P!J:0%W<\?V8Y@4C\1QZ$>U=M9N-#!K:+^[5O\ MR.&A_O6)OI;;_P EL'P5"GP5&[X:ZDUC6)+YCS(;LWI$C2D_-YFU8AEN<*O8 M"C,VXXA*.L8V2:VM=[/L3E[_ 'OM2;LFU]GMY?Y#VMT1XGHY9?C;XL$7^J/A33&NPO(%P?[+$);'1O M*W=<' ;MFO6J17]F4):*2KM6>]E&I^'1>9Y^V)JI?"J7R^*!/\%_+&@>(O+. M;?\ X3/6A"N<@1*EF@4?[ VD #C QT%88_2I'I:*^XZ,)I3?D>S9 [@8]\8Q M7"M=M?0VNEUL ([$?@1VI72=KI/M_P =K>09 [@8]P,8HNEU2L*Z75*QY=X MJT+XIWFI^?X-\9^'= TP6L*?8-2\,?VM.]VC2&65KQ;J(B)D:,!-I*^63D[^ M/6P=7)Z=+EQ>$K5*B?Q4ZB2MTT;6QX.983B&OBX5,MSBAA,-C6P:KSYN9 MM6:JTO=4;+XE=WV/.-8\6_'+X+T6R:\LYU57-O>1V-W<)!/R?D+Y^4\5Y>99?6P M%;ZM55[IN,XJ7(U%[WE%:72U5T?39#G6#SS"1Q>$E&+CR*I14HSJT93A&7+5 MC&I+VGQ-V2^% M]R#PS/)X(^(&L>%[M6_LKQ==3Z]X?F4%([>\X!N< M8Z?D<'M7F+?9QY=-=/N^[\CT5HEJK/:P[/M_G\J=@^9BZ[K5EX?TO4-5OF"6 M]A:R7#AI(HO,VJ=D,;3.B^;(X"*">2<#GBJI4)UIPI4K:R7->]DKV;T3LM?D M34J1I0YI;+9*U]%?2[1XQX7U";2_"OBWXI:U"T>I>(4N+JVM,&+[/96T8M]* MLU^T!,[I1N+C=N4@J"1@^K72E6I8.D]**4G?R3>ZN]G;9:GGJ7+"IB>5\DER M*-O>O==-K:=SM/A7HD_A_P %:=!>DM=WTESK%TVQXP)-1D,JQ[955E983$"" M.H."1@G@QU>,\2Z:C*ZBH;=5HWH]-?P^X[,,E"@IN48QDKZNW+I?WK[6Z]M3 MSOQ7\=Q:^+C\/? WA:[\8^)H&S?S1W6-$TQ A9S=3Z1;ZE=>;$^P212V< 3= M]_.,^SA\BC/"K'8^M'#T(M+V;;A6EJDI1C-*/*[W3N[I7MT/AL;QI4AF+R?( M,!/&XA7;K_\ ,-'E3E.//26*DY*W*URQLVD[==*#1/VC+YI);OQE\.- 0LK0 M6VD^']5U@+'DMLFGU1K9RVT[>$ &,]\#-5.'*?+;!XNO:^LJL(LFZN>Y=A=N6%+ 3JZ:W4JE2M3VT2:I*^K=KJ*]D\/6NN66CV- MMXBU"TU?68HV6^U&SM#IUM*S#R>2!$8U(WGE2>]>1B'AYU92P].5* MD[KM://*VENNZ9N5B=9 M7907.2.< @]\ 8'3../446M:5VN756_K44W32BI17,](W5[K71IZ?@SY9\>? M#+7O 6OR_%CX/0E+V#_2O%/@.U$D6G>++<&19F@M8F$:7OE7$TW",WF01-$ MP9)?J\'F=''86669FE*=11C1Q#2O2Y5>SDK.\G&,5*TF^9\SU;?YMG/#F*X? MQG^L/#<_J]/#\]?'8-2E*.)3D^?EC-5%%QIU*K2C*DDU&UK)QZJUUO0_CKX% MCU/093I_B?1I$N5LVD*:EX:\26Y+/IM\=D;HC/&R*^$60!7&#&57RZN$JY5B MN23OAJGPOI..CNK]K^\KZ>EF?59%G>&SW+H8N,7&M33C5H.RE"K"3A+9O=Q; M5I;-72>BGL[W3OB;H[^$O$['P_X\T21976,B#4++4+=BBZKI,BE6FB=5)80O MC:R@-C##.M%X2LJV'][#2=TNG+>UGOIV_J_H4G&O"5&K[M2.D7Z:I_>3P>(O MB3X*(TS6/"USXPTVT3R;77M&9C>W%O$1M>\M%65_.$7&2JY*L2V2,CI8;%M2 MIU8T)RU:D[*^SLM=6^B^1:G4PT?92BYQC\+797].C+K_ !6*'Q8JG%+O=?FO\P6+_Z=2T]/\S+3 MPQXB\;W4'B#XD;-"T71W^UV?A2VG#6C>3^^:[UFX9RCJN/FRBG:K#"T*I#"1 M=/#-5*LM'+=:;6[W>UNVI-.$L34R^?EY+N03W[?%/7K32],C ^'GA MZZAO+[5((2MMK6H6.'ATZ $J'LD:0*<*P(5F.TH%.4)/#0=5IRQ-2\(K=K5/ MFU?:+[[A6E&56-.+4<+2]^4NFBDOS:.1\=?$C7OB!KLOPK^#T\>_8J^*_']I M*\FF^&+=2M*[E* MB(-HQG/3]/Z>P%>99)MKW4[:>E_\_P/;BI)>\[OO_20 M^F,* $P!V]_R&!^E"5K]+@ERWMI?-0A 7'(.!D8Y'/?!]ZA1Y(\M.*5FF METNK6W]".503LK=UY=5\U='S=X^^%VO:%K-W\3?A'<-8>*?ENM<\*[6&B^-% MC=FGBNH?M<,<%^Z23.)0I+28*-!([R2?2X'.*5?#1RO-HJ5-*U.K)RYZ=M%9 MI232OIO;1.ZV_/\ .>&\5@\PJ<1\.5*E#&3=Z^'IQA[.OI'FYN9QEK*$6[/5 M[:VOC:)XP\"_%>X@T[6))?AW\6=+8P2V+Q>7/6+5FN3JVHRDXKK=I+R[]&4<4X+,I4Z&/=/*,V MC[M7#U7.BX5%KRTIUXPC+I;E=371-O1=\S?&+PU^XMDT;QY8#'D7-QC3M3CC M )7SBMQ&DCL,C<%;D#GGGSHPRJHFZM6>$K)ZP:;AIOROV>MM+>]?5Z=OK'+' M4TI8>,<33EMS3A>V_,JBE&+6EK*.MXV?NN\7_"7_ !=G/EP_#6S@;/$MYK$1 MB0DX!V^8A8#KQ(/ZTU0RE;X]>7NM?H_R%'$XZ3Y?JWL7_P!?8)?C;\REJFB: MO>V;:O\ %GQG;:!H<+&670M.N8=*TWRTR[PWE_)*SWF^%6C,*-*[ _(P8UK3 MBY5%1RK!SQ=72TH1F]+I1;T=KR:W<5V\N?&8S#8"DL1G&8T,OPZ3]VM4IKGM M%RDHOG3;Y4W91D[/2[W\V?Q7K_Q3N!X ^"^GR>&?AM!,UKK?Q'M[2>W4Q*C- MJ.G:#%.(2;V7S(XQ,VZ7>Q=BBJV_UUA2]O[O;B2\O;B3+S3L= MW?:H.$"K@#YW&8VKC:KE5ES+5*-](I]%_F?!X=P2P6 348J/MJK24ZT MHIWE.RM=OF=HJUY.VYW@ Z >V,>U<5K/M8]I/Y"]/P_I1:W]=@"@ H * M$/2C\+?H"T]$,VD>G'3DC\,8HM&Z;6L=A.]N6*48_P!=+?J>6^.OA%X&\? S M:SI2VVLPC%EXDTAFT[7K"1.89+>_A'[QHFPRQW"S1Y&=E>I@LWS#!VC3JNI1 MB[>RJM.GR]4HM25M7K9:O5'@YIPOD^:QE*K@J5'&27N8FCSX>M3FOAGSX>5* MM+-\EQ-GC(I2J\E-?#'GK2Q,G:]KO6W7H2-\/OVG[P>7-\9O#=I&3AI+/0+ZT_P_:,"I)33[>Z)F)(;( M+QH0<-&0:BIQ!&C3]GE.#AEC5U[2*A*HXI6CJX)Q:=G?FD[I:Z7>V#X%JUY. M?%&(U?FC1JJM3HTY-WERQCB7#E7!&H523R6QD]SS7SDIUJM25?%8BIB<1)*+J3E*_* MK65G)K2VCW/NL)@\+E]&.%P%"G@L+!MJC2A%1YFVY2NDGJW=K;[D:@4KGH>O M7C'IV-0UMR^ZT=3M9I12\NC]=/T8\<>V/TQ3V^0EIY6Z!0 4 % !0 AX'3.. MW3I0 BMG/&-OU'\U'Z4 ?GQ\+O'/C/4O^"@O[1W@74/%7B"\\%^'_AWX4U#1 M/"MSJMY/X?TF^N=+^'LMS>:?I4DIM[2YF>_O"\D<:LWVF3)^:O5Q5*G3RW"U M(12G*.K_ / OU."$YRQ5*JZL$W;6S5>^O M_;D?N78N,Y?7I4WI&-.32]'2_P V??F1&.,#)/MDYQT ] *\P[!XZ#MQT]/S M _D* %H * "@ H * "@!N<$\XQ^&*EW;Y4K)=?Z_S%:UWT70_+C4OC/\?OVM M/B3XW^&W[-7B6T^%'PM^'5[<>&O&_P 6M0L8M5UO6]86^O+9H_!L:1GR8S#9 M2/"89K:?RMEW)>PK<6L-Q[L<)0P-&-;$6JU'9PIR7=)6:EVW;:LFN^_E/$3Q M=7V%*4J*U3E%VM:[6L6K7M;?J;H_9;_:O^&%K/XG^%?[6_BOQQXGMX)+N[\' M_%+2WU3PMXINHXY)A81R7VNWKZ +AE$"RQ*)%+KFZ@0-*D_7L)7_ '4\#2H1 M5O?A""EZW45ZO7IUV=/"8G#^_'$U*MOLN4W^;9X[^Q9X]U_XF_MM?'KQGXK\ M,W'@WQ5>_"[1M)\4^&+AMSZ1XG\+W'@3PQK\$8,KE+1K_299H%#G*6)^">G^!O!>@1R>7;S>*?%&J:C;:/]E]B5=6^YO_(=:52.82]G=ODD MNNW[KMVT/H*3]DC]HKQPDNO_ !+_ &Q_B/IWBZS5YL,RP>&DJ2R^E52V%/@9^TWXFA^(?A+XC+:67PN^,]EHZ:&6 MUY[MK!O#WBQ(V\LSFXN=.C=@99H&U"PEDN+B"\?[!IB:%#'T:F+P<8T)4OCI M122T@W=1AHE[MEHDW?[5QPJRH5(TIR[W.__:U\>_$CX&^* MOA%\;-$\7:DWPJM_%NE^!?BQX D%H=*FT?Q UZEEXOM[B2W\RUNK(2W*MLG0 MS3KI4?S;61N3*Y0Q%.MA*E&*J*$IQJ2BN:ZE3LDVN;:^FUKZ6N/%\]"I3KJ< MO9W47!-I?#+I>W1'W1!,DL4 MKVOI;Y?/;H=J:JQ4X^ZK7T_X!\%?!SXF_$KXV_M9?%K4M#\3ZE:?L^_!U)?A M]!HBPVL>G>*?B%;K):ZC>K2GY M6L=_Z"TP"@#G?%+:DGASQ"VC@_VK'HFJ-IH4 L;]=/N39! >"WVL1<&KHN4: M]/;DNM.NZ$FDJB=]%I^!\!?\$NX]#B_9DMVTUD.M3>._&$GC!6<&X374N;:* M)94X9/\ B2+H[@%N2Q%'EB^14]=OYI6W?H>=EJH^SK/::GI] MW;[S]%Y #U!Q]<=B#T_V2W<<@=Z\9IRC9+Y:7/1C-J5OA2V=F?F9\%XM+B_X M*4?M2#267RV^&GAB6_6-@R#6);?X>'41D' ?S5&]>H?S 0.,^U7?L\FP-.47 M%QG*6MOA:M'9[VCKT_3S:3C_ &A5L]I?HB75QX=7_@J%H+Z[)"EXO[/[CPQY MTJQYUYKS4(V2W5O]==MH3ZX$0A9O30 M_,'_ (*B?94^&GP?E@++XJ@^-WAYO#/DEFG+'1]<%V(XE'S#S4TU21DJ[PC@ MLN?>X=5L5BKIRHJC[RC_ #\RYM[?WK:GFYE%7PRIR2G%J]_EY=_ZV/N3XX_# M33OC!\)?'OPWU6"*:/Q5X>O;*R:1]JVNMP#[7X?OPX4^6]IKEMI]QG!&8B&W M*3GR\-5E0K0J?#&-17_PN"3Z^MM>QVUZ3J82=.37,MNBO?3IV/SF^%7[7&J? M#3]AWQ9=>+)"GQ@^!]]>_!Q-!U./;J4>M1,UCX'DU.U\P/-:VVC(?.NUW^:O MAJ_D03,G[WUZV"]MCZ%6,;8>LU)RV6KCS7LG;=-Z:W=KZV\REBUAL'*A.[K1 M3BK)=FENU^1]G_L;?">^^#OP#\%>'M8\P^*=?BNO''C%YWW3_P#"2>*3!J-S M!,!$N)+2S>QL&SR#IH^\69CY^98A8C&SG3NJ,8Q@DTN:\$HMZ-Z-IVUO:UTM MCNP%*5"@E4LY2;E[M[6DTUNEK;?\SZI Q^']*XMOD=,4U>XM(H* &E1[CG\L M# _E4N2A9[)"MNMKGY%W&B_%?]@;XJ>./&GA3P=J/Q-_9A^(^MCQ5XOM]!MQ M>^+?A[>RM>+(8+6*6&-;>WFU&V6.XD5[>>R@C@FDMYH%GC^BC*AFE&G3J5%2 MK05HR;6NB;T;5T^6]D[K36SU\B-"M@JKG"+G!MMQ5_->>U^W_ ]$N/\ @HKH M/Q&MI/"7[.7PR^(WC_XK:Q$UIX>T_5]!L-+\+Z/?R*PBU'Q9J\>OR)8:9:'] MY(2Z0S>4T8N8=VY>:.51H/FK8B$8?W97^6O+TOKNMK/=;RQM6:Y*>&ESKR?_ M ,B>5_L5> ?BCX*_;%^.C_%>*:[\6ZM\/K37_$VNV.GW2>&;CQ'XKU+P=XDU M#3=&U&5/)N(;&2^DLU6.20*FG%5>0)YCZYA7I5L%2I4;.%/W4]M$I=/R1SX2 MA4^M.51.,KW:[?/3\C'_ &IOA'\2?B1^W)I.H?#9[K1O%/@_X1Z1XU\&Z]>6 M=TOAZ\\5>$]9O[JS\/7VJ>0L%E'?Q7,MO)(TLF%8AU2)Y9K?IR_&8:AEOL,0 M^6.D;W5[MU5LVKV4F[*[:6B;LBZE"?U^33:]R7_N+_(]B@_X*6>"?!-N/#/Q MO^&GQ.\"?%/1U^R>)?#EGX>TRYT:758U 9_#M]>^)8)+G3;K,"/"OQ*_;8^-7@KX MX?$SP=K/PV^!'PMNQJ_PL\(:M(D'B#Q5X@MK[3KQ-8U>WEBS_9LEW86\TLJ1 M1P216MM:VDUQNFN3K6K4^NKWP]C4Q%> MG5;:IRM)>C::_ _5F0*J@YQCOUZ@KR .A.,UX+YI+D^&4MOEK^2/7:-?V]O!WB>ZTN=_A+XRTVU^(OBZ6U?;9W'B;X;6EO8+ MI.IP &(?:[ZY\+.KLA>2+5=7,;9BDQ]'1S2%+)JF%:4L337+%W2=K-)[-KE6 MN^MM]3R:N E4S",EI3O=JVFZ/UP5%4+@8V@!>V .W'UKYVYZZ7*DOY=/N'T M% 'GGC#XE>$O!.L^#M$\0:QIFFW7C#5[G2;$7VK:;IGV?R-#UK61>3QWUY"[ MVLDFB_8$:-'!N=0MH^#( UQI2G!S2LHK3?\ 3MN_^')'O"VG2/Y4=[XCU?3]#LY) M#M_=I<:I<01N_P RY4,3\PJHTZE[1CMTCT^[;83G&*NW9+_ACSSQ+\7/!WA' MQ3\.M"+8+_2K;P]I.F^"]%MM58I+.Y@NHXUN% MD\M<;F?!&=8TJTHSNV^1K1M]79:>7X$JM1CY>B/1].\4>%]5TJRUS2_$&A:G MHFHR>5I^L:?JMA>Z5?RB9K8)9ZA;3O!A2G#XHZ>8S0O%OA/Q1%58 M+CS P$4A5L]!FATZBLG&UM4GY=5Z=7T'S1WZKJ9VF>+O 7BK4;_3-"\2>$_$ MNK: R_VGI^DZOI&M:CH*M*O!:7BO5KR^ M?]=B7[-[Q3MY+]3B_ GQL\&^+?AMH_Q0U>^T[P-H.JW^NZ=&_BG6=)T^WM[C M0M?U?P_-&=2GN([5VGET>>=$$A;RRPZQMB73JIVY=8]-_P"MAJ45:VEM%H>H MVNOZ%>Z4NN66L:7=Z*UHU^NKV]]:S:8;%%D=[S[='(8/LJK#,6EW[%\E\D;& MQ+A46G+9K;Y?U]S[,:E%==CGX?'OA;6-#O-;\)Z]X<\70PQZC'9G0_$6C7-I M>ZCIM@;^73AJD5V]K;2K!);R2/)(!#%.L\F(OF+I4JO,TUV_';2VM]DM==-] M YXIZ$4_Q!\+Z#H>@:UXUU[PWX(&MV=I-'%K_B?1+>U6\N;..YEL+/5I;Q+7 M56B!?$MI(\WEOITMV_P F'/$V]8\6^%O#MM87NO\ MB30M"L]4NH+'3+O5]6L-,MM0O;I&DM;2QGO;B-+NYFC5FCCB9V<#*@U*I2]Z MR>F_E_E_P/(3J1C97]#H%((!'3MVJ(KENNQ2::TTL>2_$+PO'K7BKX17;:+' MJD.E>.-6N-3N9+!+I-.TV3X9?$&QBFN9&1C#;-K-YI4:#(7SY82,/AAO2J.G M&45IM;7MY;?@9U*7/;EER6[+_)H^([7X;^+=&\._%S0O%UG\1-0\1ZQXQ^(N MHII&E?"7PKXZM/BA8:[KVJ:KX0N+3XB7WA"]@TF%]+OK#3(X?$6K6']B'3S; MKBPM;::7K52/[MQY8I=.9^[:]]$U?O;EZV;TN<_+.G>&L^7KWOKYVM>V_0]_ MTO1D\'>.8KWXB>$O$WBNSF^%WP]T+PYXK_X1.]^(E]H-]X>MM=M?%NA:G_PC M6DWUWI>J:A>75EJ,NIVEC#::DS"-I0=.BB,N7N/DFHN,I:)VO>2::L[.RTL[ M66G9CC=M*4'R_P"2].YSWB'P/8^,OBU^S9JVD_"?4M"\"^%O$GQPU+4;;4?" MEIH^F07EYX?M[?0_$^IZ)&-VFIJ^HK/-9QZO:VE\TPWRVL$B*S1"'VOM(MH MM&M]0URWUC0F\/Z1=:A:+$EO>2V-YK4%K,Y8VL5S,\92-7%$*JM#FE\,KV>M MM&EUZ/7O=7UEN7FOL/1=SE_$^AVOC34_@7;?"WX;:_X!U;PK\0_#7B;7=5U' MP3J_P[MO!O@72K:5O$_A62YETZSL_$1U>U:/1%T;2[J_M))9?M\C/%8Q2W%* M7+[2]1235DN[N^VSOUV2:M9*R5YZ>XU8\^^!W@O7/ ^E_#'4_B9X"\2ZGHUK MX8^)VAV^DS>#-8\4W?@/Q-=_&'Q+X@BUJY\,:7IE[J%L/$OAJZTV.#4K>P8Q M1Z%!%(\4>H%E( M8_ ][:_#G5_CMX"U.R^%FJ6-MX3OO%EC9>&$T/7-9L?"&I2VD-Q>W?BAK77X MO#DMI'<:JW@QI6MGGU0)24DK+GBY*,DY*[MK=>\_>M%:>5^H?VX:7ZJ2>KO;Y+LMG<7.UM&UE^AAZ M/X \3Z1XD-[XGC\<^'$U3X8?#"QT37M*^$>E?%**P@TGP3I&BZ[X,FMV\(Z_ MJOA?4K+Q';ZGJC6TMK'87AU;>YDFMG0S[6&NBEK)OWFMWH]&NBMO==-!IS7V M&MOZV*,'PZU7P=X%\,Z\=!^)6J>.=%B^+UWX-\'^*_A];_$?PS?Z#XPU?3;V M+X:6C7>G)H\9NK:XFEB@DL6J,X^_%./+)*[NTUO MJGUM>S[W2T3;2]G*I9ZT^796O>_S6UC]%-'>X?2M->[LTTZZ>QM7N=/B=)([ M"X:!&FLXY(P%>.&0M&K $(.*\^>DGY'5!.$4M[&D0#C(^[T[8_SQ^(!Z@5G M>WD:_H-V+D< 8].!^('!_&ES-=;6"R[">6O'!&W'0L.BE0#@\C!Z'(S@]0*$ MWW"R72UAQ5?3'T)7]01Z?S]:=W]P6MY"%%../NDD8)&,Y!Z'IST/'3T&"["R M[">6@_A[YY).",\@$\'G''8 = %=KJ%EV$\J/CY1\HVCKG (."T'Q-ILVC^(M&T MS7-)N#&9]-U:QMK^RE:&1)H'>VN8WC,D4T<4D;[=R/$CH0R*1<)RB]':PFE: MUC"\-_#GP+X0N)[WPWX6T?2=0NH?LUSJEO:JVK7%JKJZ6<^K3%[R:R1U!2W: M GRAPHIC 9 g286083dsp001a.jpg GRAPHIC begin 644 g286083dsp001a.jpg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end GRAPHIC 10 g286083dsp002.jpg GRAPHIC begin 644 g286083dsp002.jpg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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Jun. 07, 2022
Document And Entity Information [Line Items]  
Security Exchange Name NASDAQ
Entity Address, Country FR
Entity Tax Identification Number 00-0000000
Amendment Flag false
Entity Central Index Key 0001613780
Document Type 8-K
Document Period End Date Jun. 07, 2022
Entity Registrant Name DBV Technologies S.A.
Entity Incorporation State Country Code I0
Entity File Number 001-36697
Entity Address, Address Line One 177-181 avenue Pierre Brossolette
Entity Address, Postal Zip Code 92120
Entity Address, City or Town Montrouge
City Area Code 33
Local Phone Number 1 55 42 78 78
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Fair Value Measured at Net Asset Value Per Share [Member]  
Document And Entity Information [Line Items]  
Security Exchange Name NASDAQ
Security 12b Title Ordinary shares, nominal value €0.10 per share
Adr [Member]  
Document And Entity Information [Line Items]  
Security Exchange Name NASDAQ
Security 12b Title American Depositary Shares, each representing one- half of one ordinary share, nominal value €0.10 per share
Trading Symbol DBVT
XML 12 d286083d8k_htm.xml IDEA: XBRL DOCUMENT 0001613780 2022-06-07 2022-06-07 0001613780 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2022-06-07 2022-06-07 0001613780 dei:AdrMember 2022-06-07 2022-06-07 NASDAQ NASDAQ FR 00-0000000 false 0001613780 8-K 2022-06-07 DBV Technologies S.A. I0 001-36697 177-181 avenue Pierre Brossolette 92120 Montrouge 33 1 55 42 78 78 false false false false Ordinary shares, nominal value €0.10 per share NASDAQ American Depositary Shares, each representing one- half of one ordinary share, nominal value €0.10 per share DBVT false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 3 22 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d286083d8k.htm d286083dex991.htm dbvt-20220607.xsd dbvt-20220607_def.xml dbvt-20220607_lab.xml dbvt-20220607_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 19 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d286083d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "dbvt-20220607_def.xml" ] }, "inline": { "local": [ "d286083d8k.htm" ] }, "labelLink": { "local": [ "dbvt-20220607_lab.xml" ] }, "presentationLink": { "local": [ "dbvt-20220607_pre.xml" ] }, "schema": { "local": [ "dbvt-20220607.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 6, "total": 6 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 2, "nsprefix": "dbvt", "nsuri": "http://www.dbv-technologies.com/20220607", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d286083d8k.htm", "contextRef": "duration_2022-06-07_to_2022-06-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:SecurityExchangeName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d286083d8k.htm", "contextRef": "duration_2022-06-07_to_2022-06-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:SecurityExchangeName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dbvt_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.dbv-technologies.com/20220607", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dbvt_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.dbv-technologies.com/20220607", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AdrMember": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "American Depositary Receipt (or American Depositary Share, ADS).", "label": "Adr [Member]", "terseLabel": "Adr [Member]" } } }, "localname": "AdrMember", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "terseLabel": "Fair Value Measured at Net Asset Value Per Share [Member]" } } }, "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.dbv-technologies.com//20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-3" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r7": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 20 0001193125-22-169395-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-169395-xbrl.zip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